Heart and Blood Diseases

All Conditions

Thrombosis

Thromboembolism

Venous Thromboembolism

Embolism

Embolism and Thrombosis

Vascular Diseases

All Drugs and Chemicals

Fluorodeoxyglucose F18

Radiopharmaceuticals

Patients undergo diagnostic fludeoxyglucose F 18 PET in addition to standard methods.

Patients only undergo standard diagnostic methods.

diagnostic procedure

fludeoxyglucose F 18

Pierre-Yves Salaun, MD

RATIONALE: Diagnostic procedures, such as fludeoxyglucose F 18 positron emission tomography, may help find and diagnose cancer. It is not yet known whether standard diagnostic procedures are more effective when given with or without fludeoxyglucose F 18 positron emission tomography in finding cancer.

PURPOSE: This randomized clinical trial is studying fludeoxyglucose F 18 positron emission tomography given together with standard diagnostic procedures to see how well it works compared with standard diagnostic procedures alone in finding cancer in patients with a blood clot in a vein.

OBJECTIVES:

Primary

* Demonstrate the efficacy, in terms of increased numbers of cancer diagnoses, of PET-CT with 18-FDG in patients with idiopathic venous thromboembolism.

Secondary

* Assess the risk of cancer detected at 1 year.
* Assess whether PET allows earlier detection of cancer.
* Evaluate survival.

OUTLINE: This is a multicenter study.

All patients undergo standard (clinical and biological) diagnostic tests for cancer. Patients are randomized to 1 of 2 diagnostic arms.

* Arm I: Patients undergo diagnostic fludeoxyglucose F 18 PET in addition to standard methods.
* Arm II: Patients only undergo standard diagnostic methods. Patients are followed up for 2 years.

Standard Diagnostic Procedures With or Without Fludeoxyglucose F 18 Positron Emission Tomography in Finding Cancer in Patients With a Blood Clot in a Vein

Study of Positron Emission Tomography With 18-fluorodeoxyglucose in Detecting Cancer in Patients With Idiopathic Venous Thromboembolism

University Hospital, Brest

Gland and Hormone Related Diseases

Neoplasms

Thyroid Diseases

Carcinoma

Thyroid Neoplasms

Thyroid Nodule

Endocrine System Diseases

Endocrine Gland Neoplasms

Head and Neck Neoplasms

Patients undergo needle biopsy for collection of tissue samples. Tissue samples are analyzed using DDMS-2. Patients' medical records are also reviewed.

Diagnostic Procedure

Electronic Health Record Review

Needle Biopsy

John H. Yim

John H Yim

This clinical trial evaluates deoxyribonucleic acid (DNA) methylation signatures in diagnosing and managing thyroid nodules. The purpose of this research is to develop a new test for thyroid cancer. This test will use needle biopsies (small collections of tissue with a needle) from the thyroid to determine whether the participant has a malignant (cancer) or benign (not showing cancer) thyroid tumor. The information learned from this trial may help develop a more accurate test so that patients do not have unnecessary surgeries for nodules that are thought to be suspicious but are actually benign.

PRIMARY OBJECTIVE:

I. To evaluate the effect of Diagnostic DNA Methylation Signatures (DDMS-2) results (positive predictive value \[PPV\], negative predictive value \[NPV\], sensitivity and specificity) on physician decision-making for clinical management of 800 indeterminate thyroid nodules.

SECONDARY OBJECTIVES:

I. To determine sensitivity and specificity, PPV, NPV of DDMS-2 with 1450 needle biopsies including 800 needle biopsies with indeterminate cytopathology.

II. Compare the diagnostic accuracy between DDMS-2 and two currently used diagnostic approaches based on genetic alterations and gene expression within the same prospective cohort of 800 indeterminate needle biopsies.

OUTLINE:

Patients undergo needle biopsy for collection of tissue samples. Tissue samples are analyzed using DDMS-2. Patients' medical records are also reviewed.

Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules

Evaluation of DNA Methylation Signatures in Diagnosis and Management of Thyroid Nodules

The sensitivity of DDMS-2 will be estimated by taking the ratio of the number of true thyroid cancer specimens diagnosed as cancer by DDMS and the total number of thyroid cancer specimens. Will also determine the 95% confidence intervals.

The specificity will be estimated by taking the ratio of the number of true benign nodules diagnosed as benign by DDMS and the total number of true benign thyroid nodules. Will also determine the 95% confidence intervals.

PPV (number of true thyroid cancer specimens by DDMS / number of thyroid cancers diagnosis by DDMS) will be calculated. Will also determine the 95% confidence intervals.

NPV (number of true benign nodules diagnosed by DDMS/number of benign diagnosis by DDMS) will be calculated. Will also determine the 95% confidence intervals.

National Cancer Institute (NCI)

City of Hope Medical Center

Substance Related Disorders

Behaviors and Mental Disorders

Blood and Lymph Conditions

Skin and Connective Tissue Diseases

Mouth and Tooth Diseases

Symptoms and General Pathology

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Diseases and Abnormalities at or Before Birth

Nutritional and Metabolic Diseases

Rare Diseases

Tobacco Use Disorder

Anemia

Lichen Planus

Mouth Neoplasms

Precancerous Conditions

Leukoplakia

Leukoplakia, Oral

Fanconi Syndrome

Fanconi Anemia

Erythroplasia

Lichenoid Eruptions

Exanthema

Skin Diseases

Skin Diseases, Papulosquamous

Substance-Related Disorders

Chemically-Induced Disorders

Mental Disorders

Psychotic Disorders

Anemia, Hypoplastic, Congenital

Anemia, Aplastic

Hematologic Diseases

Syndrome

Bone Marrow Failure Disorders

Pancytopenia

Congenital Bone Marrow Failure Syndromes

Bone Marrow Diseases

Genetic Diseases, Inborn

DNA Repair-Deficiency Disorders

Metabolic Diseases

Pathological Conditions, Anatomical

Mouth Diseases

Stomatognathic Diseases

Oral Cancer

Erythroplakia

Lip and Oral Cavity Cancer

Oral Leukoplakia

Congenital Aplastic Anemia

Participants' oral cavities are inspected by a clinician using a standard white light headlamp. Participants then undergo oral mucosa examination using wide-field reflectance and fluorescence imaging, and/or fluorescence spectroscopy imaging. Standard oral brush biopsies are also performed and examined microscopically. Participants may undergo repeated imaging procedures and biopsy during subsequent follow up visits.

Cytology Specimen Collection Procedure

Mouth tissue examined microscopically for cytologic features

Diagnostic Microscopy

Undergo standard white light headlamp oral examination

Undergo widefield fluorescent and reflectance imaging

Fluorescence Imaging

Fluorescence Spectroscopy

Ann M Gillenwater

This clinical trial studies widefield fluorescence and reflectance imaging, fluorescence spectroscopy, and tissue samples in regularly examining (monitoring) participants at risk for developing oral cancer. All tissue and cells are made of tiny particles. Some of these particles give off small amounts of light. This light is called fluorescence. Fluorescent imaging use instruments that shine different wavelengths (colors) of light in the mouth taking fluorescence pictures through a portable head light or by taking fluorescent and reflectance pictures through a dental microscope using a digital camera. Fluorescent spectroscopy uses a small probe placed gently against the lining of the mouth and the tissue is exposed to small amounts of fluorescent light that is then collected with a special camera and a computer to be analyzed. Checking mouth tissue samples under a microscope may also help detect abnormal cells. Diagnostic procedures, such as fluorescence and reflectance imaging, fluorescence spectroscopy imaging, and tissue samples, may help doctors detect pre-cancer or early cancer when it may be easier to treat.

PRIMARY OBJECTIVES:

I. To compare images of oral mucosa, obtained at various wavelength combinations including 350 nm, 380 nm, 400 nm, and 450 nm excitation, to standard white light images, pathologic analysis of any biopsied tissue when available, and carcinogenic progression.

OUTLINE:

Participants' oral cavities are inspected by a clinician using a standard white light headlamp. Participants then undergo oral mucosa examination using wide-field reflectance and fluorescence imaging, and/or fluorescence spectroscopy imaging. Standard oral brush biopsies are also performed and examined microscopically. Participants may undergo repeated imaging procedures and biopsy during subsequent follow up visits.

Widefield Fluorescence and Reflectance Imaging Systems and Oral Tissue Samples in Monitoring Participants at Risk for Developing Oral Cancer

Fluorescence &Amp; Reflectance Imaging to Detect Oral Neoplasia

Oral mucosa obtained at various wavelength combinations including 350 nm, 380 nm, 400 nm, and 450 nm excitation will be compared to standard white light images, pathologic analysis of any biopsied tissue when available, and carcinogenic progression. Diagnostic methods will be compared with each other by forming 2x2 tables and computing the chi-square statistics for the McNemar test. Kappa statistic will also be calculated for comparing the chance corrected agreement between various diagnostic methods.

M.D. Anderson Cancer Center

Carcinoma, Transitional Cell

Urinary Bladder Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Urinary Bladder Diseases

Urologic Diseases

Male Urogenital Diseases

Transitional Cell Carcinoma

Micronutrients

Vitamins

Selenium

Tocopherols

Vitamin E

Tocotrienols

alpha-Tocopherol

Trace Elements

Antioxidants

Protective Agents

Tocopherol

Tocotrienol

selenium

vitamin E

biopsy

chemoprevention

cryopreservation

cytology specimen collection procedure

gene expression analysis

immunohistochemistry staining method

laboratory biomarker analysis

medical chart review

mutation analysis

polymerase chain reaction

quality-of-life assessment

questionnaire administration

study of socioeconomic and demographic variables

K. K. Cheng, MD

RATIONALE: Studying different factors that effect patients with newly diagnosed bladder cancer may help doctors learn more about the disease, improve the ability to plan cancer treatment, and help patients live more comfortably.

PURPOSE: This clinical trial is studying different factors affecting patients with newly diagnosed bladder cancer.

OBJECTIVES:

* To assess the effect of lifestyle factors (e.g., smoking, dietary habits, fluid intake, or environmental exposures) on the recurrence and progression of bladder cancer.
* To assess the impact of selenium and/or vitamin E on the progression and recurrence of bladder cancer.
* To study health-related quality of life and its association with recurrence and progression of bladder cancer.
* To establish a bladder cancer tissue bank that will comprise blood, urine, and bladder tissue.
* To study the predictive effect of molecular markers on the recurrence and progression of bladder cancer.

OUTLINE: This is a multicenter study.

The study will be based on a cohort of patients with newly detected bladder cancer in all 16 urological centres within the West Midlands, commencing in late 2005 for a period of 5 years. This research project consists of 5 individual studies: CRUK-BCPP-2005-01-COHORT, CRUK-BCPP-2005-01-MARKERS, CRUK-BCPP-2005-01-QOL, CRUK-BCPP-2005-01-TISSUE-BANK, and CRUK-BCPP-2005-01-TREATMENT. Patients may participate in all or only some of these individual studies.

Peer Reviewed and Funded or Endorsed by Cancer Research UK.

Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer

Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial)

University Hospital Birmingham

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Standard Diagnostic Procedures With or Without Fludeoxyglucose F 18 Positron Emission Tomography in Finding Cancer in Patients With a Blood Clot in a Vein	NCT00964275	Thromboembolism Unspecified Adu...	diagnostic proc... fludeoxyglucose...	18 Years -	University Hospital, Brest
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules	NCT05229341	Thyroid Gland C...	Diagnostic Proc... Electronic Heal... Needle Biopsy	18 Years -	City of Hope Medical Center
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules	NCT05229341	Thyroid Gland C...	Diagnostic Proc... Electronic Heal... Needle Biopsy	18 Years -	City of Hope Medical Center
Widefield Fluorescence and Reflectance Imaging Systems and Oral Tissue Samples in Monitoring Participants at Risk for Developing Oral Cancer	NCT00542373	Erythroplakia Fanconi Anemia Lichen Planus Oral Cavity and... Oral Cavity Leu... Oral Neoplasm Premalignant Le... Tobacco Use Dis...	Cytology Specim... Diagnostic Micr... Diagnostic Proc... Fluorescence Im... Fluorescence Sp...	18 Years -	M.D. Anderson Cancer Center
Standard Diagnostic Procedures With or Without Fludeoxyglucose F 18 Positron Emission Tomography in Finding Cancer in Patients With a Blood Clot in a Vein	NCT00964275	Thromboembolism Unspecified Adu...	diagnostic proc... fludeoxyglucose...	18 Years -	University Hospital, Brest
Standard Diagnostic Procedures With or Without Fludeoxyglucose F 18 Positron Emission Tomography in Finding Cancer in Patients With a Blood Clot in a Vein	NCT00964275	Thromboembolism Unspecified Adu...	diagnostic proc... fludeoxyglucose...	18 Years -	University Hospital, Brest
Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer	NCT00553124	Bladder Cancer	selenium vitamin E biopsy chemoprevention cryopreservatio... cytology specim... diagnostic proc... gene expression... immunohistochem... laboratory biom... medical chart r... mutation analys... polymerase chai... quality-of-life... questionnaire a... study of socioe...	18 Years -	National Cancer Institute (NCI)

Spots Global Cancer Trial Database for diagnostic procedure